{
    "Rank": 307,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00900133",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CASE7104"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA043703",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA043703"
                        },
                        {
                            "SecondaryId": "CASE-7104",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Case Comprehensive Cancer Center"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer",
                "OfficialTitle": "A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2015",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "January 2005"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "April 2006",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2006",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "May 9, 2009",
                "StudyFirstSubmitQCDate": "May 9, 2009",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "May 12, 2009",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "October 1, 2015",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 2, 2015",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "John Pink, PhD",
                    "ResponsiblePartyOldOrganization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer.\n\nPURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nDetermine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast.\n\nOUTLINE: This is a pilot study.\n\nPatients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.\n\nPROJECTED ACCRUAL: A total of 60 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage I breast cancer",
                        "stage II breast cancer",
                        "stage IIIA breast cancer",
                        "stage IIIB breast cancer",
                        "stage IIIC breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Case-Only"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Cross-Sectional"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples With DNA",
                    "BioSpecDescription": "Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers."
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "60",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Other",
                            "InterventionName": "immunoenzyme technique",
                            "InterventionDescription": "Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression."
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "laboratory biomarker analysis",
                            "InterventionDescription": "Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Correlation between circulating levels of calgranulin A and calgranulin B and the presence of estrogen receptor negative breast cancer",
                            "PrimaryOutcomeTimeFrame": "upon diagnosis"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed primary adenocarcinoma of the breast\n\nStage I-III disease\nNo evidence of metastatic disease\nNewly diagnosed disease\n\nHormone receptor status:\n\nEstrogen receptor-positive- or -negative tumor\n\nPATIENT CHARACTERISTICS:\n\nSex\n\nNot specified\n\nMenopausal status\n\nNot specified\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNot specified\n\nRenal\n\nNot specified\n\nOther\n\nNot pregnant\nNo Crohn's disease\nNo arthritis\nNo psoriasis\nNo lupus erythematosus\nNo multiple sclerosis\nNo other severe active inflammation\nNot C-reactive protein positive\nNo HIV positivity\nNo other serious medical or psychiatric illness\n\nPRIOR CONCURRENT THERAPY:\n\nRadiotherapy\n\nNo prior radiotherapy for breast cancer\n\nSurgery\n\nNo prior organ transplantation\n\nOther\n\nNo prior systemic therapy for breast cancer",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Patients With Newly Diagnosed Stage I,II,III Breast Cancer. Primary care clinic",
                "SamplingMethod": "Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "John Pink, PhD",
                            "OverallOfficialAffiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44106",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M7806",
                            "InterventionBrowseLeafName": "Estrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}